WGc-043 injection for EBV-positive solid tumors
Part of Cancer, Infections clinical trials.
This trial tests an investigational drug (WGc-043) for people with advanced solid tumors that are positive for the Epstein-Barr virus (EBV). The goal is to see if the drug is safe and how well it works, and it might help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must be advanced, not able to be cured by surgery or other treatments, and test positive for EBV.
- You should be well enough to take care of yourself (ECOG score 0-1) and have a life expectancy of at least 3 months.
- You must have at least one tumor that can be measured by imaging tests (and it hasn't been previously treated with radiation unless it's clearly grown).
- Your major organs (like heart, liver, kidneys, and blood cells) must be working well enough, and you must agree to use effective birth control during the trial and for 6 months after.
- You must not have had other cancers recently (except for certain cured skin or bladder cancers), no active brain or spinal cord tumors that are not controlled, no serious heart problems, and no active autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new mRNA-based immunotherapy for diseases caused by the Epstein-Barr virus (EBV), such as certain cancers and conditions after a stem cell transplant. The treatment aims to help your immune system fight the virus and the disease.
This trial tests an investigational mRNA vaccine (WGc-043) that aims to help your immune system fight EBV-positive lymphoma cells. If you have tried standard treatments and your lymphoma is still active, this vaccine might offer a new option.
This trial tests a new medicine called WGb-0301, given by injection, for people with certain blood cancers (B-cell lymphoma or lymphocytic leukemia) that have come back or not improved with other treatments. The goal is to see if this drug can help control the cancer and what side effects it might cause.
This trial tests a vaccine that may help prevent diseases caused by the Epstein-Barr virus (EBV) after a stem cell transplant. It could lower the risk of infections and related complications.
This trial tests an experimental cell therapy that targets cells infected with the Epstein-Barr virus (EBV). It is for patients with certain blood cancers or post-transplant lymph disorders caused by EBV that have not responded to standard treatments or who cannot receive them.
This trial tests a new drug called EGL-001 for people with advanced solid tumors that have already been treated with immunotherapy. The goal is to see if the drug is safe and effective against cancer that has not responded to other treatments.
Hear when a new Advanced EBV-positive Malignant Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.